Amber N. McElroy

Amber N. McElroy

Auto-generated profile, based on publicly available information

Amber N. McElroy

Department of Pediatrics, University of Minnesota Medical School, Minneapolis, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 November 2022 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
MNMonica E. Neugebauer
Monica E. Neugebauer
AHAlvin Hsu
Alvin Hsu
MAMandana Arbab
Mandana Arbab
NKNicholas A. Krasnow
Nicholas A. Krasnow
AMAmber N. McElroy
Amber N. McElroy
DLDavid R. Liu
David R. Liu
Cytosine base editors (CBEs) are larger and can suffer from higher off-target activity or lower on-target editing efficiency than current adenine base editors (ABEs). To develop a CBE that retains the small size, low off-target activity and high on-target activity of current ABEs, we evolved the highly active deoxyadenosine deaminase TadA-8e to perform cytidine deamination using phage-assisted continuous evolution. Evolved TadA cytidine deaminases contain mutations at DNA-binding residues that alter enzyme selectivity to strongly favor deoxycytidine over deoxyadenosine deamination. Compared to commonly used CBEs, TadA-derived cytosine base editors (TadCBEs) offer similar or higher on-target activity, smaller size and substantially lower Cas-independent DNA and RNA off-target editing activity. We also identified a TadA dual base editor (TadDE) that performs equally efficient cytosine and adenine base editing. TadCBEs support single or multiplexed base editing at therapeutically relevant genomic loci in primary human T cells and primary human hematopoietic stem and progenitor cells. TadCBEs expand the utility of CBEs for precision gene editing.

19 November 2019 in Nature Communications
Verified
Journal Article
Open access
BWBeau Webber
Beau Webber
CLCara-Lin Lonetree
Cara-Lin Lonetree
MKMitchell G. Kluesner
Mitchell G. Kluesner
MJMatthew J. Johnson
Matthew J. Johnson
EPEmily J. Pomeroy
Emily J. Pomeroy
BMBranden S Moriarity
Branden S Moriarity
The fusion of genome engineering and adoptive cellular therapy holds immense promise for the treatment of genetic disease and cancer. Multiplex genome engineering using targeted nucleases can be used to increase the efficacy and broaden the application of such therapies but carries safety risks associated with unintended genomic alterations and genotoxicity. Here, we apply base editor technology for multiplex gene modification in primary human T cells in support of an allogeneic CAR-T platform and demonstrate that base editor can mediate highly efficient multiplex gene disruption with minimal double-strand break induction. Importantly, multiplex base edited T cells exhibit improved expansion and lack double strand break-induced translocations observed in T cells edited with Cas9 nuclease. Our findings highlight base editor as a powerful platform for genetic modification of therapeutically relevant primary cell types.

1 June 2013 in Molecular Therapy
Verified
Journal Article
Open access
MOMark J Osborn
Mark J Osborn
CSColby G Starker
Colby G Starker
AMAmber N McElroy
Amber N McElroy
BWBeau R Webber
Beau R Webber
MRMegan J Riddle
Megan J Riddle
JTJakub Tolar
Jakub Tolar
Recessive dystrophic epidermolysis bullosa (RDEB) is characterized by a functional deficit of type VII collagen protein due to gene defects in the type VII collagen gene (COL7A1). Gene augmentation therapies are promising, but run the risk of insertional mutagenesis. To abrogate this risk, we explored the possibility of using engineered transcription activator-like effector nucleases (TALEN) for precise genome editing. We report the ability of TALEN to induce site-specific double-stranded DNA breaks (DSBs) leading to homology-directed repair (HDR) from an exogenous donor template. This process resulted in COL7A1 gene mutation correction in primary fibroblasts that were subsequently reprogrammed into inducible pluripotent stem cells and showed normal protein expression and deposition in a teratoma-based skin model in vivo. Deep sequencing-based genome-wide screening established a safety profile showing on-target activity and three off-target (OT) loci that, importantly, were at least 10 kb from a coding sequence. This study provides proof-of-concept for TALEN-mediated in situ correction of an endogenous patient-specific gene mutation and used an unbiased screen for comprehensive TALEN target mapping that will cooperatively facilitate translational application.

1 March 2016 in Molecular Therapy
Verified
Journal Article
Open access
PDF file
Mark OsbornMark Osborn
Mark Osborn
BWBeau R Webber
Beau R Webber
FKFriederike Knipping
Friederike Knipping
CLCara-Lin Lonetree
Cara-Lin Lonetree
NTNicole Tennis
Nicole Tennis
BBBruce R Blazar
Bruce R Blazar
Present adoptive immunotherapy strategies are based on the re-targeting of autologous T-cells to recognize tumor antigens. As T-cell properties may vary significantly between patients, this approach can result in significant variability in cell potency that may affect therapeutic outcome. More consistent results could be achieved by generating allogeneic cells from healthy donors. An impediment to such an approach is the endogenous T-cell receptors present on T-cells, which have the potential to direct dangerous off-tumor antihost reactivity. To address these limitations, we assessed the ability of three different TCR-α-targeted nucleases to disrupt T-cell receptor expression in primary human T-cells. We optimized the conditions for the delivery of each reagent and assessed off-target cleavage. The megaTAL and CRISPR/Cas9 reagents exhibited the highest disruption efficiency combined with low levels of toxicity and off-target cleavage, and we used them for a translatable manufacturing process to produce safe cellular substrates for next-generation immunotherapies.

29 December 2014 in Human Gene Therapy
Verified
Journal Article
Closed access
MOMark J. Osborn
Mark J. Osborn
RGRichard Gabriel
Richard Gabriel
BWBeau R. Webber
Beau R. Webber
ADAnthony P. DeFeo
Anthony P. DeFeo
AMAmber N. McElroy
Amber N. McElroy
JTJakub Tolar
Jakub Tolar
Genome engineering with designer nucleases is a rapidly progressing field, and the ability to correct human gene mutations in situ is highly desirable. We employed fibroblasts derived from a patient with Fanconi anemia as a model to test the ability of the clustered regularly interspaced short palindromic repeats/Cas9 nuclease system to mediate gene correction. We show that the Cas9 nuclease and nickase each resulted in gene correction, but the nickase, because of its ability to preferentially mediate homology-directed repair, resulted in a higher frequency of corrected clonal isolates. To assess the off-target effects, we used both a predictive software platform to identify intragenic sequences of homology as well as a genome-wide screen utilizing linear amplification-mediated PCR. We observed no off-target activity and show RNA-guided endonuclease candidate sites that do not possess low sequence complexity function in a highly specific manner. Collectively, we provide proof of principle for precision genome editing in Fanconi anemia, a DNA repair-deficient human disorder.

1 February 2020 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
Mark OsbornMark Osborn
Mark Osborn
GNGregory Newby
Gregory Newby
AMAmber N. McElroy
Amber N. McElroy
FKFriederike Knipping
Friederike Knipping
SNSarah C. Nielsen
Sarah C. Nielsen
JTJakub Tolar
Jakub Tolar